Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Back to Search
Print
Bookmark Trial

NCT03760146

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Accel Resarch Sites
Birmingham, Alabama, 35216, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.

2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.

3. Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or
planned receipt through study participation.


2. History of microbiologically proven invasive disease caused by S pneumoniae.


3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive
pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with
or without dialysis, clinically unstable cardiac disease, or any other disorder that,
in the investigator's opinion, excludes the subject from participating in the study.


4. Pregnant female subjects or breastfeeding female subjects.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pneumococcal DiseaseSafety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
NCT04642079
  1. Chamblee, Georgia
  2. Sioux City, Iowa
  3. Binghamton, New York
  4. Dayton, Ohio
  5. Austin, Texas
  6. San Antonio, Texas
  7. Murray, Utah
  8. Provo, Utah
  9. Salt Lake City, Utah
  10. Salt Lake City, Utah
  11. Salt Lake City, Utah
  12. South Jordan, Utah
  13. Syracuse, Utah
  14. Charlottesville, Virginia
  15. Charlottesville, Virginia
  16. Charlottesville, Virginia
ALL GENDERS
15 Months+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Milano, Milan
  2. Firenze,
  3. Foggia,
  4. Haarlem,
  5. Hoofddorp,
  6. Oslo,
  7. Westmead, New South Wales
  8. Nedlands, Western Australia
  9. Nedlands, Western Australia
  10. Brussels,
  11. Edegem,
  12. Jindrichuv Hradec,
  13. Jindrichuv Hradec,
  14. Jindrichuv Hradec,
  15. Pardubice,
  16. Praha 3,
  17. Praha 6,
  18. Sezemice,
  19. Tallinn,
  20. Tallinn,
  21. Tallinn,
  22. Tallinn,
  23. Tartu,
  24. Espoo,
  25. Helsinki,
  26. Helsinki,
  27. Järvenpää,
  28. Kokkola,
  29. Oulu,
  30. Pori,
  31. Seinajoki,
  32. Tampere,
  33. Turku,
  34. Bydgoszcz,
  35. Bydgoszcz,
  36. Debica,
  37. Krakow,
  38. Krakow,
  39. Leczna,
  40. Lodz,
  41. Lubon,
  42. Siemianowice Slaskie,
  43. Torun,
  44. Trzebnica,
  45. Warszawa,
  46. Warszawa,
  47. Wroclaw,
  48. Wroclaw,
  49. Bratislava,
  50. Bratislava,
  51. Detva,
  52. Horne Srnie,
  53. Humenne,
  54. Humenné,
  55. Kosice,
  56. Liptovská Osada,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Isumi-city, Chiba
  2. Fukuoka-city, Fukuoka
  3. Fukuoka-shi, Fukuoka
  4. Osaka-City, Osaka
  5. Ritto-Shi, Shiga
  6. Nagoya-shi, Aichi
  7. Toyota-shi, Aichi
  8. Chiba-shi, Chiba
  9. Funabashi-city, Chiba
  10. Yotsukaido-shi, Chiba
  11. Yotsukaido-shi, Chiba
  12. Fukui-shi, Fukui
  13. Fukuoka-City, Fukuoka
  14. Fukuoka-city, Fukuoka
  15. Iizuka, Fukuoka
  16. Kasuga-city, Fukuoka
  17. Gifu-city, Gifu
  18. Ebetsu Shi, Hokkaido
  19. Sapporo shi, Hokkaido
  20. Sapporo, Hokkaido
  21. Akashi-City, Hyōgo
  22. Kawasaki-shi, Kanagawa
  23. Kumamoto Shi, Kumamoto
  24. Kumamoto-shi, Kumamoto
  25. Kuwana-city, MIE
  26. Nagano-shi, Nagano
  27. Kawachinagano, Osaka
  28. Ureshino-shi, Saga
  29. Hanyu-shi, Saitama
  30. Kumagaya-shi, Saitama
  31. Fuchu-city, Tokyo
  32. Nishitokyo-shi, Tokyo
  33. Setagaya-ku, Tokyo
  34. Setagaya-ku, Tokyo
  35. Shinjuku-ku, Tokyo
  36. Suginami-ku, Tokyo
  37. Kofu-city, Yamanashi
  38. Tsuru-shi, Yamanashi
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Miami Lakes, Florida
  2. Miami, Florida
  3. Wilmington, North Carolina
  4. Oklahoma City, Oklahoma
  5. Wauwatosa, Wisconsin
  6. Birmingham, Alabama
  7. Mobile, Alabama
  8. Chandler, Arizona
  9. Phoenix, Arizona
  10. Tempe, Arizona
  11. Redding, California
  12. San Diego, California
  13. San Diego, California
  14. Walnut Creek, California
  15. Coral Gables, Florida
  16. Crystal River, Florida
  17. Hialeah, Florida
  18. Jacksonville, Florida
  19. Miami, Florida
  20. Orlando, Florida
  21. Orlando, Florida
  22. Savannah, Georgia
  23. Stockbridge, Georgia
  24. Meridian, Idaho
  25. El Dorado, Kansas
  26. Wichita, Kansas
  27. Wichita, Kansas
  28. Metairie, Louisiana
  29. New Orleans, Louisiana
  30. Elkridge, Maryland
  31. Rockville, Maryland
  32. Saint Louis, Missouri
  33. Norfolk, Nebraska
  34. Omaha, Nebraska
  35. Las Vegas, Nevada
  36. Las Vegas, Nevada
  37. Binghamton, New York
  38. Endwell, New York
  39. Charlotte, North Carolina
  40. Greensboro, North Carolina
  41. Hickory, North Carolina
  42. Raleigh, North Carolina
  43. Raleigh, North Carolina
  44. Rocky Mount, North Carolina
  45. Rocky Mount, North Carolina
  46. Fargo, North Dakota
  47. Cincinnati, Ohio
  48. Cincinnati, Ohio
  49. Cleveland, Ohio
  50. Franklin, Ohio
  51. Warwick, Rhode Island
  52. Little River, South Carolina
  53. Mount Pleasant, South Carolina
  54. Bristol, Tennessee
  55. Nashville, Tennessee
  56. Austin, Texas
  57. Cedar Park, Texas
  58. Fort Worth, Texas
  59. Fort Worth, Texas
  60. Houston, Texas
  61. McKinney, Texas
  62. Pearland, Texas
  63. San Antonio, Texas
  64. Tomball, Texas
  65. Tomball, Texas
  66. Draper, Utah
  67. Salt Lake City, Utah
  68. Salt Lake City, Utah
  69. South Jordan, Utah
  70. Norfolk, Virginia
  71. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
Official Title  ICMJE A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER
Brief Summary A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Pneumococcal Disease
Intervention  ICMJE
  • Biological: 20vPnC
    20vPnC
  • Biological: 13vPnC
    Pneumococcal conjugate vaccine
  • Biological: PPSV23
    Pneumococcal polysaccharide vaccine
    Other Name: Pneumovax 23
  • Other: Saline
    Placebo
Study Arms  ICMJE
  • Experimental: 60 years and above 20vPnC/Saline
    20vPnC and saline
    Interventions:
    • Biological: 20vPnC
    • Other: Saline
  • Active Comparator: 60 years and above 13vPnC/PPSV23
    13vPnC and PPSV23
    Interventions:
    • Biological: 13vPnC
    • Biological: PPSV23
  • Experimental: 50 through 59 years of age 20vPnC
    20vPnC
    Intervention: Biological: 20vPnC
  • Experimental: 18 through 49 years of age 20vPnC
    20vPnC
    Intervention: Biological: 20vPnC
  • Active Comparator: 50 through 59 years of age 13vPnC
    13vPnC
    Intervention: Biological: 13vPnC
  • Active Comparator: 18 through 49 years of age 13vPnC
    13vPnC
    Intervention: Biological: 13vPnC
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 11, 2020)		3902
Original Estimated Enrollment  ICMJE
 (submitted: November 29, 2018)		3880
Actual Study Completion Date  ICMJE December 16, 2019
Actual Primary Completion Date December 9, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female adults >/= 18 years of age (from the 18th birthday) at enrollment and older.
  2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.
  3. Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.

Exclusion Criteria:

  1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
  2. History of microbiologically proven invasive disease caused by S pneumoniae.
  3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
  4. Pregnant female subjects or breastfeeding female subjects.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Sweden,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03760146
Other Study ID Numbers  ICMJE B7471007
2018-004279-11 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP